Top Stocks
Dividend Investing
ETFs
Stock Comparison
About Us
Working with TipRanks
Follow Us
HLS Therapeutics Inc (DE:74D)
FRANKFURT:74D
reports
HLS Therapeutics Inc (74D) Stock Price & Analysis
0 Followers
74D Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€4.58 - €11.03
Previous Close€4.58
Volume0.00
Average Volume (3M)N/A
Market Cap
€165.42M
Enterprise Value€220.97M
Total Cash (Recent Filing)$21.16M
Total Debt (Recent Filing)$91.63M
Price to Earnings (P/E)N/A
Beta0.81
Next Earnings
May 11, 2023EPS Estimate
-€0.11Next Dividend Ex-Date
Apr 27, 2023Dividend Yield
0.15 (3.18%)Share Statistics
EPS (TTM)N/A
Shares Outstanding32,377,223
10 Day Avg. Volume0
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)1.57
Price to Sales (P/S)3.04
Price to Cash Flow (P/CF)12.20
P/FCF Ratio-432.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.63
Enterprise Value/Gross Profit3.94
Enterprise Value/Ebitda10.29
Forecast
1Y Price Target
€11.53Price Target Upside151.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
74D FAQ
What was HLS Therapeutics Inc’s price range in the past 12 months?
HLS Therapeutics Inc lowest stock price was €4.58 and its highest was €11.03 in the past 12 months.
What is HLS Therapeutics Inc’s market cap?
Currently, no data Available
When is HLS Therapeutics Inc’s upcoming earnings report date?
HLS Therapeutics Inc’s upcoming earnings report date is May 11, 2023 which is in 51 days.
How were HLS Therapeutics Inc’s earnings last quarter?
HLS Therapeutics Inc released its earnings results on Mar 16, 2023. The company reported -€0.187 earnings per share for the quarter, missing the consensus estimate of -€0.079 by -€0.109.
Is HLS Therapeutics Inc overvalued?
According to Wall Street analysts HLS Therapeutics Inc’s price is currently Undervalued.
Does HLS Therapeutics Inc pay dividends?
HLS Therapeutics Inc pays a Quarterly dividend of €0.03 which represents an annual dividend yield of 3.18%. See more information on HLS Therapeutics Inc dividends here
What is HLS Therapeutics Inc’s EPS estimate?
HLS Therapeutics Inc’s EPS estimate is -€0.11.
How many shares outstanding does HLS Therapeutics Inc have?
Currently, no data Available
What happened to HLS Therapeutics Inc’s price movement after its last earnings report?
HLS Therapeutics Inc reported an EPS of -€0.187 in its last earnings report, missing expectations of -€0.079. Following the earnings report the stock price went down -19.649%.
Which hedge fund is a major shareholder of HLS Therapeutics Inc?
Currently, no hedge funds are holding shares in DE:74D
---
HLS Therapeutics Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.84%
12-Months-Change
Fundamentals
Return on Equity
-16.49%
Trailing 12-Months
Asset Growth
-6.05%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
HLS Therapeutics Inc
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada and the United States.
---
---